MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Tricida Retained Earnings 2011-2025 | TCDA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -810 M | - | -369 M | -192 M | -89.4 M | -48.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -48.1 M | -810 M | -302 M |
Quarterly Retained Earnings Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -882 M | -856 M | -828 M | -810 M | -760 M | -721 M | -687 M | -634 M | -634 M | -634 M | -634 M | -369 M | -369 M | -369 M | -369 M | -192 M | -192 M | -192 M | -192 M | -89.4 M | -89.4 M | -89.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -89.4 M | -882 M | -481 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.21 | -7.63 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.67 | -2.55 % | $ 1.44 B | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.47 | -2.08 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.36 | -2.37 % | $ 633 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.6 | 0.07 % | $ 2.06 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 6.88 | 0.36 % | $ 427 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 50.08 | -0.16 % | $ 1.63 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.29 | -1.56 % | $ 22.5 M |  China |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 5.36 | -8.71 % | $ 706 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.8 | 1.99 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 7.19 | -0.07 % | $ 2.62 B | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.48 | 1.77 % | $ 1.22 B | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.11 | -2.14 % | $ 57.8 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.87 | 7.18 % | $ 20.3 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.83 | -1.19 % | $ 238 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.75 | -1.13 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.63 | -0.41 % | $ 4.5 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.37 | 1.28 % | $ 320 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 13.87 | 0.95 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.51 | -16.94 % | $ 8.08 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.5 | -2.21 % | $ 135 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.69 | 3.68 % | $ 7.29 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 9.92 | 0.22 % | $ 705 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.58 | -1.87 % | $ 27.8 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 9.6 | -5.43 % | $ 5.93 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.72 | 0.88 % | $ 18 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 12.33 | 0.69 % | $ 14.9 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |